Conditions · Pancreatic cancer
Pancreatic cancer — biological & vaccine options
Prefer to look first? Browse the live map without signing up.
5 open options
- TRIALNARECRUITING
Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
Claudin18.2 CAR-T cells — 1 site
- TRIALPHASE1RECRUITING
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
CEA-targeted CAR-T cells — 2 sites
- TRIALPHASE1 / PHASE2RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
EBNK-001 + IL-15 + Pembrolizumab — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2B694 · A2B543 · xT CDx with HLA-LOH Assay — 12 sites
- TRIALPHASE1RECRUITING
The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)
TMT101 Injection — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.